Drugs / ERB-257
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00722202 Comparator | Oct → Nov 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00722501 Comparator | Aug → Nov 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERB-257 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00722501 ↗ |
| Route | Intravenous | “ERB-257 Administered Intravenously as a 30-Minute Infusion” NCT00722202 ↗ |